Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOS | P01100 | 2/20 | 0.61 |
| ▸ | JUN | P05412 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.46 |
| ▸ | PPARG | P37231 | 5/20 | 0.46 |
| ▸ | PPARD | Q03181 | 5/20 | 0.46 |
| ▸ | PPARA | Q07869 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4285922 | 0.91 | FOS (0.64) | FOSJUNPOLBFFAR1PPARG | |
| SCHEMBL4279563 | 0.82 | JUN (0.76) | FOSJUNPOLBFFAR1PPARG | |
| SCHEMBL4284099 | 0.80 | FOS (0.48) | FOSJUNFFAR1PPARGPPARD | |
| SCHEMBL4282700 | 0.78 | JUN (0.81) | FOSJUNFFAR1PPARGPPARD | |
| SCHEMBL4276620 | 0.78 | JUN (0.81) | FOSJUNFFAR1PPARGPPARD | |
| SCHEMBL27908941 | 0.76 | FOS (0.56) | FOSJUNPTGER1 | |
| SCHEMBL2968375 | 0.76 | JUN (0.61) | FOSJUNFFAR1PPARGPPARD | |
| SCHEMBL1527292 | 0.76 | FOS (1.00) | FOSJUNPOLBPPARGPPARD | |
| SCHEMBL31191805 | 0.76 | FOS (1.00) | FOSJUNPOLBPPARGPPARD | |
| SCHEMBL2968731 | 0.76 | JUN (0.70) | FOSJUNPOLBFFAR1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| CN-101284865-A | Novel compound and medical use thereof | TOYAMA CHEMICAL CO LTD (JP) | 2008-10-15 | — | — | CN | disclosed |
| CN-100378063-C | Novel compound and medical use thereof | TOYAMA CHEMICAL CO LTD (JP) | 2008-04-02 | — | — | CN | disclosed |
| US-7314888-B1 | Compounds and medicinal use thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| EP-1127869-A1 | NOVEL COMPOUNDS AND MEDICINAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | SP1, AP1G1, AP1M1 | FOS 63/4885JUN 20/4885POLB 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.